2024
O 09 Radiotherapy utilization and outcomes from a contemporary study of brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin lymphoma
Hoppe B, Castellino S, Pei Q, Charpentier A, Mailhot-Vega R, Roberts K, Parikh R, Flampouri S, Kelly K, Hodgson D. O 09 Radiotherapy utilization and outcomes from a contemporary study of brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin lymphoma. International Journal Of Particle Therapy 2024, 11: 100032. DOI: 10.1016/j.ijpt.2024.100032.Peer-Reviewed Original ResearchHigh-risk Hodgkin lymphomaRadiotherapy utilizationHodgkin lymphomaBrentuximab vedotinRadiotherapyLymphomaChemotherapy
2023
Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study
Milgrom S, Kim J, Pei Q, Lee I, Hoppe B, Wu Y, Hodgson D, Kessel S, McCarten K, Roberts K, Lo A, Cole P, Kelly K, Cho S. Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study. British Journal Of Haematology 2023, 201: 1192-1199. PMID: 36922022, PMCID: PMC10247420, DOI: 10.1111/bjh.18734.Peer-Reviewed Original ResearchConceptsRapid early respondersEvent-free survivalTotal lesion glycolysisBaseline total lesion glycolysisIntensive therapyRisk stratificationTumor burdenHodgkin's lymphomaEarly respondersMTV/TLGFour-year event-free survivalBaseline metabolic tumor burdenExcellent event-free survivalHigh-risk Hodgkin lymphomaChildren's Oncology Group studyPoor event-free survivalMaximum standardized uptake valueResponse-adapted approachBaseline PET scanMetabolic tumor burdenStandardized uptake valueIntensified therapyLesion glycolysisBaseline PETTumor SUVImportance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy
Hoppe B, McCarten K, Pei Q, Kessel S, Alazraki A, Mhlanga J, Lai H, Eutsler E, Hodgson D, Roberts K, Charpentier A, Keller F, Voss S, Wu Y, Cho S, Kelly K, Castellino S. Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2023, 116: 1025-1030. PMID: 36868525, PMCID: PMC10363760, DOI: 10.1016/j.ijrobp.2023.02.020.Peer-Reviewed Original ResearchConceptsCentral reviewDeauville scoreCentral imaging reviewRadiation therapyResponse assessmentHodgkin's lymphomaImaging reviewInstitutional reviewFluorodeoxyglucose positron emission tomography/High-risk Hodgkin lymphomaPositron emission tomography responseConcordance rateEmission tomography/Real-time central reviewCohen κ statisticAreas of diseaseSystemic therapyTreating institutionPediatric patientsLymphoma trialsTomography responseTomography/Treatment allocationClinical trialsPatients
2021
Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group
Parikh RR, Kelly KM, Hodgson DC, Hoppe BS, McCarten KM, Karolczuk K, Pei Q, Wu Y, Cho SY, Schwartz C, Cole PD, Roberts K. Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2021, 112: 890-900. PMID: 34767937, PMCID: PMC9038118, DOI: 10.1016/j.ijrobp.2021.10.152.Peer-Reviewed Original ResearchConceptsInvolved-field radiation therapySlow early responseClassical Hodgkin lymphomaBulky diseaseOncology GroupHodgkin's lymphomaRetrospective analysisChildren's Oncology Group protocolsHigh-risk Hodgkin lymphomaRadiation treatment volumesCycles of doxorubicinHigh-risk patientsPhase 3 studyTime of progressionChildren's Oncology GroupPatterns of failureInitial siteABVE-PCConsolidation RTEligible patientsField relapseInitial relapseMedian followRelapse siteStage IIIBPET-Based Quantification of Baseline Metabolic Tumor Burden Improves Risk Stratification in High-Risk Hodgkin Lymphoma: A Children's Oncology Group Study
Milgrom S, Kim J, Hoppe B, Pei Q, Wu Y, Lo A, Kessel S, McCarten K, Roberts K, Hodgson D, Schwartz C, Friedman D, Kelly K, Cho S. PET-Based Quantification of Baseline Metabolic Tumor Burden Improves Risk Stratification in High-Risk Hodgkin Lymphoma: A Children's Oncology Group Study. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s79-s80. DOI: 10.1016/j.ijrobp.2021.07.192.Peer-Reviewed Original ResearchRapid early respondersSlow early respondersMetabolic tumor volumeTotal lesion glycolysisBaseline metabolic tumor burdenHigh-risk Hodgkin lymphomaBaseline tumor burdenMetabolic tumor burdenTumor burdenIntensive therapyHodgkin's lymphomaPET scansEarly respondersCutoff valueEvent-free survival rateChildren's Oncology Group studyPositron emission tomography scanMaximum standardized uptake valueCycles of chemotherapyInitial disease burdenNodular sclerosis histologyResponse-adapted approachBaseline PET scanKaplan-Meier analysisAge 15.5 years
2020
Patterns of Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children’s Oncology Group
Parikh R, Hoppe B, Hodgson D, McCarten K, Pei Q, Cho S, Schwartz C, Cole P, Kelly K, Roberts K. Patterns of Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children’s Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: s36-s37. DOI: 10.1016/j.ijrobp.2020.07.2140.Peer-Reviewed Original Research
2019
Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group
Kelly KM, Cole PD, Pei Q, Bush R, Roberts KB, Hodgson DC, McCarten KM, Cho SY, Schwartz C. Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group. British Journal Of Haematology 2019, 187: 39-48. PMID: 31180135, PMCID: PMC6857800, DOI: 10.1111/bjh.16014.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCyclophosphamideDoxorubicinDrug Administration ScheduleDrug MonitoringEtoposideFemaleHodgkin DiseaseHumansIfosfamideMaleNeoplasm StagingPositron-Emission TomographyPrednisoneProspective StudiesRadiotherapy, AdjuvantRecurrenceTreatment OutcomeVincristineVinorelbineYoung AdultConceptsHigh-risk Hodgkin lymphomaABVE-PCOncology GroupHodgkin's lymphomaEarly respondersRapid early respondersEnd of chemotherapyEvent-free survivalOverall survival rateResponse-adapted therapyChildren's Oncology GroupTreatment of childrenPET-positive lesionsAlkylator exposureOS ratesActive diseaseTreat analysisPediatric patientsRadiotherapy volumeClinical evidenceEarly progressionRadiation volumeRecent trialsPositive lesionsSER patients
2015
Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children's Oncology Group
Kelly K, Cole P, Chen L, Roberts K, Hodgson D, McCarten K, Cho S, Schwartz C. Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children's Oncology Group. Blood 2015, 126: 3927. DOI: 10.1182/blood.v126.23.3927.3927.Peer-Reviewed Original ResearchHigh-risk Hodgkin lymphomaRapid early responseCompletion of chemotherapyABVE-PCStage IIIBOncology GroupOverall survivalPediatric patientsHodgkin's lymphomaHigh riskLong-term overall survivalDose-intensive chemotherapyRisk-adapted radiotherapyEnd of chemotherapyEvent-free survivalBone marrow involvementPhase III studyRelapse/progressionBest predictive factorChildren's Oncology GroupHigh-risk groupEnhanced risk stratificationTreatment of childrenPET-positive lesionsBulky involvement